AR013374A1 - Empleo de derivados de hidroxicumarona o-sustituidos para la preparacion de un medicamento como agentes antitumorales y antimetastalticos, dichoscompuestos y composiciones farmaceuticos que los comprenden - Google Patents

Empleo de derivados de hidroxicumarona o-sustituidos para la preparacion de un medicamento como agentes antitumorales y antimetastalticos, dichoscompuestos y composiciones farmaceuticos que los comprenden

Info

Publication number
AR013374A1
AR013374A1 ARP980103732A ARP980103732A AR013374A1 AR 013374 A1 AR013374 A1 AR 013374A1 AR P980103732 A ARP980103732 A AR P980103732A AR P980103732 A ARP980103732 A AR P980103732A AR 013374 A1 AR013374 A1 AR 013374A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
alkyl
group
substituted
integer
Prior art date
Application number
ARP980103732A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR013374A1 publication Critical patent/AR013374A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

Empleo de los derivados de hidroxicumarona O-sustituidos de formula general (I), en donde: R y R están independientemente entre sí, seleccionadosentre el hidrogeno, alquilo de 1 a 6 átomos de carbono, estirilo y cicloalquilo de3 a 6 átomos de carbono o, tomados conjuntamente con elcarbono al cual están unidos, forman un grupo cicloalquilo de 3 a 6 átomos de carbono; x es 0 o 1; A está seleccionado entre los grupos siguientes:-(CH2)n-, -CH2CH=CHCH2-, -CH2-CH=CH-CH=CH-CH 2-, -CH2-CH=CH-CH2-CH2-, -CH2-CH2- CH=CH-CH2-, -CH2-CH=CH-CH2-CH2-CH2-, -CH2-CH2-CH=CH-CH2-CH2-, -CH2-CH2-CH2-CH=CH-CH2-, -CH2-CHOH-CHOH-CH2-, -(CH2)q-O-(CH2)q, -CH2-A-CH2-, en donde q es un numero entero del 2 al 3 y n es un numero entero del2 al 6, y A es un grupocicloalquilo de 3 a 7 átomos de carbono; B es o bien: (i) -N(R1)-(CH2)m-N(R2)-, en el cual m es un numero entero de 2 a 6, R1 se selecciona del grupo formadopor hidrogeno, metilo, etilo, propilo, isopropilo, y R2 se seleccionadel grupo formado por alquilo de 1 a 6 átomos de carbono, bencilo, fenilo, naftiloo indanilo opcionalmente substituido por un grupo seleccionado entre el cloro, bromo, yodo, fluor, alquilo de 1 a 6 átomos de carbono, hidroxilo, amino,carboxilo, alcoxilo de 1 a 4 átomos de carbono, mono o dialquilo de 1 a 4 átomos de carbono-amino, alcoxicarbonilo de 1 a 4 átomos de carbono, mercapto,alquiltio de 1 a 4 átomos de carbono; o bien: formula (ii), T se selecciona entre -CH2-C:::CH, -C:::C H, -(CH2)pR3, -CH=CH-R3, -CH2-NHCO-R3-(CH2)p-O-R3,-CH(NH2)-CH2R3, en donde p es 0 o un numero entero de 1 a 4, R3 se selecciona entre fenilo, naftilo, bifenilo, opcionalmente subtituido con un gruposeleccionado entre cloro, bromo, yodo,fluor, alqu ilo de 1 a 6 átomos de carbono, ciano, nitro, mono o polifluoroalquilo, -SO2(alquilo de 1 a 4 átomos
ARP980103732A 1997-07-31 1998-07-29 Empleo de derivados de hidroxicumarona o-sustituidos para la preparacion de un medicamento como agentes antitumorales y antimetastalticos, dichoscompuestos y composiciones farmaceuticos que los comprenden AR013374A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97113190 1997-07-31
EP98106946 1998-04-16

Publications (1)

Publication Number Publication Date
AR013374A1 true AR013374A1 (es) 2000-12-27

Family

ID=26145681

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103732A AR013374A1 (es) 1997-07-31 1998-07-29 Empleo de derivados de hidroxicumarona o-sustituidos para la preparacion de un medicamento como agentes antitumorales y antimetastalticos, dichoscompuestos y composiciones farmaceuticos que los comprenden

Country Status (21)

Country Link
US (1) US6200989B1 (es)
EP (1) EP1012147B1 (es)
JP (1) JP3241711B2 (es)
KR (1) KR100343067B1 (es)
AR (1) AR013374A1 (es)
AT (1) ATE308535T1 (es)
AU (1) AU745839B2 (es)
BR (1) BR9811589A (es)
CA (1) CA2296476A1 (es)
DE (1) DE69832184D1 (es)
HR (1) HRP20000031A2 (es)
HU (1) HUP0004221A2 (es)
ID (1) ID24525A (es)
IL (1) IL134193A0 (es)
MA (1) MA26528A1 (es)
NO (1) NO20000366D0 (es)
PE (1) PE106099A1 (es)
PL (1) PL338614A1 (es)
TR (1) TR200000272T2 (es)
UY (1) UY25114A1 (es)
WO (1) WO1999006387A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736869B2 (en) * 1999-01-30 2001-08-02 Roche Diagnostics Gmbh O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents
WO2003046207A2 (en) * 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
AU2002358158A1 (en) * 2001-12-19 2003-06-30 D. Collen Research Foundation Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
WO2004076444A2 (en) * 2003-02-25 2004-09-10 F. Hoffmann-La Roche Ag Novel hydroxycoumaranone derivatives as antitumor and antimetastatic
ES2535436T3 (es) * 2006-10-27 2015-05-11 The University Of Tokyo Compuesto amídico o sal del mismo, e inhibidor de la formación de biopelícula, eliminador de biopelícula, y bactericida, utilizando cada uno el compuesto amídico o la sal del mismo
US8258307B2 (en) 2006-11-07 2012-09-04 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
ES2919779T3 (es) 2017-06-20 2022-07-28 Imbria Pharmaceuticals Inc Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco
CA3073656C (en) 2017-09-22 2024-03-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
EP3707135A1 (en) 2017-11-06 2020-09-16 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
MX2020006115A (es) 2017-12-13 2020-11-09 Praxis Biotech LLC Inhibidores de la vía de respuesta al estrés integrada.
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
KR20210021519A (ko) * 2018-06-05 2021-02-26 프락시스 바이오테크 엘엘씨 통합 스트레스 반응 경로의 저해제
US11318133B2 (en) 2019-06-12 2022-05-03 Praxis Biotech LLC Modulators of integrated stress response pathway
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2901336A1 (de) 1979-01-15 1980-07-24 Boehringer Mannheim Gmbh Neue arylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3209271A1 (de) * 1982-03-13 1983-09-15 Boehringer Mannheim Gmbh, 6800 Mannheim Bicyclische phenolether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3587711T2 (de) * 1984-08-13 1994-04-28 Biotech Australia Pty Ltd Minaktivin.
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands

Also Published As

Publication number Publication date
PL338614A1 (en) 2000-11-06
AU745839B2 (en) 2002-04-11
NO20000366L (no) 2000-01-25
MA26528A1 (fr) 2004-12-20
AU9155998A (en) 1999-02-22
ATE308535T1 (de) 2005-11-15
KR100343067B1 (ko) 2002-07-03
CA2296476A1 (en) 1999-02-11
JP2001512113A (ja) 2001-08-21
US6200989B1 (en) 2001-03-13
KR20010022362A (ko) 2001-03-15
NO20000366D0 (no) 2000-01-25
PE106099A1 (es) 1999-11-11
UY25114A1 (es) 2001-01-31
HUP0004221A2 (hu) 2001-04-28
HRP20000031A2 (en) 2000-10-31
BR9811589A (pt) 2000-09-19
DE69832184D1 (de) 2005-12-08
ID24525A (id) 2000-07-20
EP1012147A2 (en) 2000-06-28
TR200000272T2 (tr) 2000-09-21
WO1999006387A3 (en) 1999-04-22
WO1999006387A2 (en) 1999-02-11
JP3241711B2 (ja) 2001-12-25
IL134193A0 (en) 2001-04-30
EP1012147B1 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
AR013374A1 (es) Empleo de derivados de hidroxicumarona o-sustituidos para la preparacion de un medicamento como agentes antitumorales y antimetastalticos, dichoscompuestos y composiciones farmaceuticos que los comprenden
RS53279B (en) MONODISPERSE MIXTURES OF PEGYLATED NALOXOL
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
PA8586401A1 (es) 4-piperazinilbencenosulfonilindoles y uso de los mismos
AR064280A1 (es) Composicion plaguicida que comprende un compuesto sintetico util como agente de nodulacion de plantas leguminosas y un compuesto fungicida
ES2112140B1 (es) 3-arilbenzofuranonas como estabilizantes
PT96890A (pt) Processo para a preparacao de novos derivados com estrutura naftalenica e de composicoes farmaceuticas que os contem
ES2178038T3 (es) Nuevos derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.
AR027437A1 (es) Derivados de purina
DK0610134T3 (da) Indolderivater som 5-HT,1-lignende agonister
FI971312A0 (fi) Uudet prostaglandiinisyntaasin estäjät
ES2126068T3 (es) Derivados de estilbeno citotoxicos y composicion farmaceutica que los contiene.
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
CA2449874A1 (en) New indole derivatives with 5-ht6 receptor affinity
PT96880A (pt) Processo para a preparacao de absorventes triazinicos de luz ultravioleta e de composicoes liquidas que os contem, uteis para a estabilizacao de revestimentos altamente solidos
EA200201141A1 (ru) Производные тропана, полезные для терапии
AR064281A1 (es) Composicion plaguicida que comprende un compuesto sintetico util como agente de nodulacion de plantas leguminosas y un compuesto insecticda
YU18999A (sh) Supstituisani tricikli
HUP0500497A2 (hu) Fenoxi-piperidin-származékok, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és eljárás előállításukra
MX9100675A (es) 2-amino-1,2,3,4-tetrahidronaftalenos,3-aminocromanos y 3-aminotiocromanos substituidos en el anillo,procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2108772T3 (es) Derivados de aminofosfonato substituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DK0686142T3 (da) Polyaminderivater som radioprotektive midler
ES2080922T3 (es) Derivados de la n-sulfonil-indolina, su preparacion, y las composiciones farmaceuticas que los contienen.
BR0207644A (pt) Compostos de carbamato para uso na prevenção ou no tratamento de distúrbio bipolar

Legal Events

Date Code Title Description
FB Suspension of granting procedure